News & Updates

Show Multimedia Only

Combo therapy in IBD: Is de-escalation possible after 1 year?

15 Feb 2023 by

Clinicians should consider de-escalating combination therapy with immunomodulators to a monotherapy after 1 year in patients with inflammatory bowel disease (IBD), says an expert at Crohn’s and Colitis Congress 2023.

Combo therapy in IBD: Is de-escalation possible after 1 year?

15 Feb 2023

Single-dose azithromycin during labour prevents maternal death, sepsis

15 Feb 2023 by

Treatment with a single oral dose of azithromycin, given to women in labour who were planning a vaginal birth, significantly reduced the risk of maternal death or sepsis, according to the A-PLUS* trial presented at SMFM 2023.

Single-dose azithromycin during labour prevents maternal death, sepsis

15 Feb 2023

$Aspirin as good as heparin for thromboprophylaxis in patients with fractures$

Aspirin as good as heparin for thromboprophylaxis in patients with fractures

14 Feb 2023

Thromboprophylaxis with aspirin in patients with extremity fractures appears to prevent death and lower the incidences of deep-vein thrombosis and pulmonary embolism without any significant differences as compared with thromboprophylaxis with low-molecular-weight heparin, according to a study.

Aspirin as good as heparin for thromboprophylaxis in patients with fractures

14 Feb 2023

Elinzanetant a promising nonhormone treatment option for VMS, sleep problems

14 Feb 2023 by

The selective neurokinin (NK)-1,3 receptor antagonist elinzanetant appears to be beneficial in the treatment of vasomotor symptoms (VMS) and associated sleep disturbance in postmenopausal women, as shown in the results of the phase IIb SWITCH-1 trial.

Elinzanetant a promising nonhormone treatment option for VMS, sleep problems

14 Feb 2023

Risk model-based lung cancer screening more economical than USPSTF recommendation

14 Feb 2023

Lung cancer screening based on a risk model is more cost-effective than the 2021 recommendation by the US Preventive Services Task Force (USPSTF), meriting further consideration for the former, reports a recent study.

Risk model-based lung cancer screening more economical than USPSTF recommendation

14 Feb 2023

Statins reduce MACE in patients with normal MPI, elevated CAC score

14 Feb 2023 by

Use of moderate to high-intensity statin (MHIS) following myocardial perfusion imaging (MPI) results in fewer major adverse cardiovascular events (MACE) and is independently predictive of 24-month MACE among patients with normal stress MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.

Statins reduce MACE in patients with normal MPI, elevated CAC score

14 Feb 2023

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

14 Feb 2023

Compared with standard dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy after 1- to 3-month DAPT results in similar rates of fatal and ischaemic events, as well as lower major bleeding risk, regardless of percutaneous coronary intervention (PCI) complexity, according to a study.

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

14 Feb 2023

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

14 Feb 2023 by

Twice-yearly maintenance dosing of inclisiran reduces atherogenic lipoproteins for primary prevention of patients with elevated LDL-C* despite statin use, according to the analysis of the primary prevention cohort from the ORION-11 trial.

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

14 Feb 2023

Childhood obesity linked to cancer incidence, mortality in adulthood

14 Feb 2023

Obesity appears to put children and adolescents at higher risk of cancer incidence and mortality in adulthood, according to the results of a meta-analysis.

Childhood obesity linked to cancer incidence, mortality in adulthood

14 Feb 2023

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023 by

The use of liposomal irinotecan in combination with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX regimen) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP) in the first-line setting, according to the NAPOLI-3* trial presented at the ASCO GI 2023.

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

14 Feb 2023

News & Updates

Filter by Specialty:

Specialty:

Combo therapy in IBD: Is de-escalation possible after 1 year?

Combo therapy in IBD: Is de-escalation possible after 1 year?

Single-dose azithromycin during labour prevents maternal death, sepsis

Single-dose azithromycin during labour prevents maternal death, sepsis

Aspirin as good as heparin for thromboprophylaxis in patients with fractures

Aspirin as good as heparin for thromboprophylaxis in patients with fractures

Elinzanetant a promising nonhormone treatment option for VMS, sleep problems

Elinzanetant a promising nonhormone treatment option for VMS, sleep problems

Risk model-based lung cancer screening more economical than USPSTF recommendation

Risk model-based lung cancer screening more economical than USPSTF recommendation

Statins reduce MACE in patients with normal MPI, elevated CAC score

Statins reduce MACE in patients with normal MPI, elevated CAC score

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

Childhood obesity linked to cancer incidence, mortality in adulthood

Childhood obesity linked to cancer incidence, mortality in adulthood

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer